Michael Engsig
Förmögenhet: 24 371 $ per 2026-05-31
Förmögenhet: 24 371 $ per 2026-05-31
Michael Thyrring Engsig currently works at Nykode Therapeutics ASA, as Chief Executive Officer from 2019 and FluoGuide A, as Independent Director from 2023.
Mr. Engsig also formerly worked at Takeda A, as Director-Research & Development and KLIFO A, as EVP-Drug Development Counselling.
Mr. Engsig received his graduate degree from Technical University of Denmark.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
NYKODE THERAPEUTICS ASA 0,02 % | 2025-10-10 | 71 794 ( 0,02 % ) | 24 371 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| NYKODE THERAPEUTICS | Verkställande Direktör | 2019-01-01 |
| FLUOGUIDE A/S | Direktör/Styrelseledamot | 2023-01-01 |
| Företag | Position | Slut |
|---|---|---|
KLIFO A/S
KLIFO A/S Miscellaneous Commercial ServicesCommercial Services Provides clinical research services | Företagsledare/Principal | - |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Engages in holding or owning securities of companies | Teknisk/Vetenskaplig/F&U Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Technical University of Denmark
Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
KLIFO A/S
KLIFO A/S Miscellaneous Commercial ServicesCommercial Services Provides clinical research services | Commercial Services |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Engages in holding or owning securities of companies | Finance |
Nykode Therapeutics ASA
Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
FluoGuide A/S
FluoGuide A/S Pharmaceuticals: MajorHealth Technology Engages in the development of drugs used for the improvement of surgical outcomes by making cancer fluorescent | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån